Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2011 1
2012 3
2013 3
2015 2
2016 2
2017 2
2018 5
2019 13
2020 13
2021 8
2022 7
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators. Paz-Ares L, et al. N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25. N Engl J Med. 2018. PMID: 30280635 Free article. Clinical Trial.
BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on 50% of tumor cells). ...
BACKGROUND: Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemothe …
Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer.
Bianco A, Perrotta F, Barra G, Malapelle U, Rocco D, De Palma R. Bianco A, et al. Among authors: rocco d. Int J Mol Sci. 2019 Oct 5;20(19):4931. doi: 10.3390/ijms20194931. Int J Mol Sci. 2019. PMID: 31590386 Free PMC article. Review.
MoAbs, used as both single-agents or in combination with standard therapy for the treatment of advanced non-small cell lung cancer (NSCLC), have exhibited advantages in terms of overall survival and response rate; nivolumab, pembrolizumab, atezolizumab and more rece …
MoAbs, used as both single-agents or in combination with standard therapy for the treatment of advanced non-small cell lung cancer …
Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer.
Rocco D, Battiloro C, Della Gravara L, Gridelli C. Rocco D, et al. Drug Saf. 2019 Feb;42(2):199-209. doi: 10.1007/s40264-018-0771-y. Drug Saf. 2019. PMID: 30649741 Review.
The chimeric protein echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, resulting from the rearrangement of the homonym genes, is one of the currently targetable oncogenic drivers in anaplastic lymphoma kinase-positive non-small-cell lung cance …
The chimeric protein echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, resulting from the rearrangement of the ho …
Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer.
Rocco D, Malapelle U, Del Re M, Della Gravara L, Pepe F, Danesi R, Troncone G, Gridelli C. Rocco D, et al. Expert Opin Drug Metab Toxicol. 2020 Feb;16(2):87-96. doi: 10.1080/17425255.2020.1721460. Epub 2020 Jan 30. Expert Opin Drug Metab Toxicol. 2020. PMID: 31978315 Review.
However, apart from currently approved, recommended and employed agents (nivolumab, pembrolizumab, atezolizumab, durvalumab), several new agents are currently under development and investigation both in monotherapy and in combinational settings.Areas covered: This paper aims to d …
However, apart from currently approved, recommended and employed agents (nivolumab, pembrolizumab, atezolizumab, durvalumab), several new ag …
Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.
Rocco D, Sapio L, Della Gravara L, Naviglio S, Gridelli C. Rocco D, et al. Int J Mol Sci. 2023 Jan 26;24(3):2433. doi: 10.3390/ijms24032433. Int J Mol Sci. 2023. PMID: 36768754 Free PMC article. Review.
RET-selective tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib have revolutionized the landscape of RET-positive (RET+) advanced non-small cell lung cancer (NSCLC) treatment, thanks to their efficacy and safety profiles. ...
RET-selective tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib have revolutionized the landscape of RET-positive (RET+) advan …
Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with Immunotherapy.
Rocco D, Della Gravara L, Ragone A, Sapio L, Naviglio S, Gridelli C. Rocco D, et al. Cancers (Basel). 2023 Sep 22;15(19):4684. doi: 10.3390/cancers15194684. Cancers (Basel). 2023. PMID: 37835378 Free PMC article. Review.
Taking into account the huge epidemiologic impact of lung cancer (in 2020, lung cancer accounted for 2,206,771 of the cases and for 1,796,144 of the cancer-related deaths, representing the second most common cancer in female patients, the …
Taking into account the huge epidemiologic impact of lung cancer (in 2020, lung cancer accounted for 2,206,771 o …
The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives.
Rocco D, Gravara LD, Gridelli C. Rocco D, et al. Curr Clin Pharmacol. 2020;15(1):11-19. doi: 10.2174/1574884714666190809124555. Curr Clin Pharmacol. 2020. PMID: 31400270 Free PMC article. Review.
BACKGROUND: In the recent years, immunotherapeutics and specifically immunecheckpoints inhibitors have marked a significant shift in the diagnostic and therapeutic algorithm of Non-Small Cell Lung Cancer (NSCLC), allowing us to use immunotherapeutics alone or combin …
BACKGROUND: In the recent years, immunotherapeutics and specifically immunecheckpoints inhibitors have marked a significant shift in the dia …
Recently approved and emerging monoclonal antibody immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancer.
Rocco D, Della Gravara L, Battiloro C, Palazzolo G, Gridelli C. Rocco D, et al. Expert Opin Biol Ther. 2023 Mar;23(3):261-268. doi: 10.1080/14712598.2023.2183116. Epub 2023 Mar 8. Expert Opin Biol Ther. 2023. PMID: 36803090 Review.
INTRODUCTION: CTLA-4/PD-1/PD-L1- directed immune checkpoint inhibitors (ICIs) are one of the standard therapies for the treatment of advanced non-small cell lung cancer (NSCLC). However, some new classes of monoclonal antibodies are emerging as promising therapies f …
INTRODUCTION: CTLA-4/PD-1/PD-L1- directed immune checkpoint inhibitors (ICIs) are one of the standard therapies for the treatment of advance …
57 results